financetom
Business
financetom
/
Business
/
MicroStrategy Swings to Non-GAAP Loss in Q1, Sales Decline; Shares Drop After Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
MicroStrategy Swings to Non-GAAP Loss in Q1, Sales Decline; Shares Drop After Hours
Apr 29, 2024 1:51 PM

04:40 PM EDT, 04/29/2024 (MT Newswires) -- MicroStrategy ( MSTR ) reported a Q1 non-GAAP loss late Monday of $8.26 per diluted share, compared with earnings of $30.59 a year earlier.

Four analysts polled by Capital IQ expected a loss of $0.13.

Revenue in the quarter ended March 31 fell to $115.2 million from $121.9 million a year earlier.

Analysts surveyed by Capital IQ expected $121.4 million.

Shares of the company fell 4.9% in recent after-hours trading.

Price: 1,230.00, Change: -62.97, Percent Change: -4.87

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BigCommerce's Revenue Growth Outlook Remains 'Uninspiring' as Competition Rises, BofA Says
BigCommerce's Revenue Growth Outlook Remains 'Uninspiring' as Competition Rises, BofA Says
Mar 25, 2024
11:45 AM EDT, 03/25/2024 (MT Newswires) -- BigCommerce Holdings ( BIGC ) revenue growth outlook is uninspiring amid tough competition and macro, BofA Securities said in a note Monday. Revenue growth is crucial in this sector, and the company is expected to see a revenue growth rate of 5.7% in 2024, which is lower than the industry average, analyst Koji...
--Digital World Acquisition Completes Merger with Trump Media & Technology Group
--Digital World Acquisition Completes Merger with Trump Media & Technology Group
Mar 25, 2024
11:53 AM EDT, 03/25/2024 (MT Newswires) -- Price: 41.42, Change: +4.48, Percent Change: +12.12 ...
Rhythm Pharmaceuticals Doses First Patients in Phase 1 Trial of Potential Obesity Therapy
Rhythm Pharmaceuticals Doses First Patients in Phase 1 Trial of Potential Obesity Therapy
Mar 25, 2024
11:48 AM EDT, 03/25/2024 (MT Newswires) -- Rhythm Pharmaceuticals ( RYTM ) said Monday that the first patients were dosed in the phase 1 trial of RM-718 to treat obesity. RM-718 is a weekly melanocortin-4 receptor-specific agonist that has demonstrated the potential to reduce body weight and hunger in preclinical studies, the company said. The three-part study will evaluate the...
Affiliated Managers Group Appoints COO, CFO
Affiliated Managers Group Appoints COO, CFO
Mar 25, 2024
11:55 AM EDT, 03/25/2024 (MT Newswires) -- Affiliated Managers Group ( AMG ) said Monday that Thomas M. Wojcik has been named chief operating officer and Dava E. Ritchea chief financial officer, starting April 1. Ritchea has previously served as CFO at Sculptor Capital Management and Assured Investment Management, the company said. Wojcik and Ritchea will report to President and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved